Navigation Links
Elsevier's MEDalternatives Offers Additional Cost Saving Options for Payers and Members

TAMPA, Florida, February 6, 2013 /PRNewswire/ --

New comprehensive resource for drug therapy options and costs helps health plan payers and members save on drug spend with information on alternative therapies

Elsevier's Gold Standard, a leading drug information provider, today announced the launch of the MEDalternatives™ database, a comprehensive resource for drug therapy options designed to give health plans and their members additional drug cost savings options through access to information on alternative therapies. MEDalternatives uses only evidence-based alternatives that have comparable or better efficacy and safety, compared to current prescriptions.

MEDalternatives covers a broad range of health conditions and the widest scope of medications, including a complete offering of drugs, drug classes, and product formulations. It returns alternatives within the class of the patient's current medication and across classes, including both generics and brands, and also provides therapeutically appropriate choices among subclasses of drugs.

MEDalternatives includes complete dosing options to ensure accurate comparisons in daily/weekly regimens and monthly/yearly costs, including those for in-store purchase versus mail-order delivery.

"MEDalternatives delivers a unique payer solution that identifies safe and cost- effective medication alternatives for achieving therapy compliance and prescription cost savings," said Marianne Messer , President, Elsevier's Gold Standard. "This will help our payer and PBM clients reduce prescription drug costs, particularly those who have already maximized their brand-to-generic switching, and improve medication adherence."

MEDalternatives helps:

  • Simplify drug regimens and drive down costs for payers and patients
  • Improve compliance for healthier and less expensive outcomes
  • Payers control prescription costs by offering therapeutic alternatives on brand-to-brand drugs, as well as brand-to-generic drugs
  • Payers educate providers and members on where savings can be attained on drugs
  • PBMs (Pharmacy Benefit Managers) enforce formulary compliance
  • Help providers identify alternative therapies to reduce costs
  • Guide consumers toward more affordable, safer and more effective medication options
  • Involve consumers in these choices, knowing that cost and convenience play a central role in adherence to treatment
  • Prepare consumers to discuss options with their healthcare providers
  • Boost patients' satisfaction with their drug benefits

MEDalternatives is derived from the most technologically sophisticated drug database available today and will easily integrate within and across diverse healthcare systems.

For more information about Elsevier's Gold Standard and MEDalternatives, visit

Elsevier's Gold Standard

Based in Tampa, FL, Elsevier's Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier's Gold Standard solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To learn more about Elsevier's Gold Standard, visit

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Christopher Capot
Director, Corporate Relations

SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Robust Biopharmaceutical Pipeline Offers New Hope for Patients
2. EPIC Pharmacies offers members discounted access to online continuing education course - Management & HR Skills for Pharmacists
3. Medbox, Inc. Offers Guidance and Consultation To Washington State
4. Study Demonstrates Percutaneous Tibial Nerve Stimulation Offers More Cost-Effective OAB Treatment Than Sacral Nerve Stimulation
5. New Online Store Offers Essential Surgical-Quality Tweezers, Holiday Gift Sets and more
6. VPG MV-1 Offers Rewards Program: Get Your MV-1 in Colorado at Medved
7. SAM Medical Products Offers Product Training at the Point of Care
8. ATF Offers $10,000 Reward for Information on Armed Robberies
9. BI-LO Offers Health Giveaways With Flu Vaccinations, Encourages Community To Shield Their Health This Flu Season
10. Living with Knee Pain? Adventist Medical Center Offers New Treatment Option
11. Safe in Common Offers Experienced Advice for U.K.s Review of Needlestick Safety Regulations
Post Your Comments:
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):